Inventia Aims to Fix Drug Discovery with Validated 3D Cell Models

SYDNEY, AU – April 16, 2026 – Australian firm Inventia Life Science today launched a new product designed to address a critical pain point in pharmaceutical research: the struggle to generate reliable, reproducible data. The new offering, RASTRUM™ Validated Solutions, provides drug discovery teams with pre-made blueprints for creating complex, human-relevant 3D cell models, aiming to accelerate the path from lab bench to clinical decision.

This move comes as the pharmaceutical industry grapples with a well-documented "reproducibility crisis," where promising preclinical results often fail to translate into successful human trials. A significant part of this problem lies in the models used for testing. Traditional 2D cell cultures, grown flat in a petri dish, lack the complex architecture of human tissue, while animal models frequently fail to predict human responses. While 3D cell models have emerged as a superior alternative, their complexity has created its own set of challenges, including variability between labs and experiments. Inventia's launch seeks to provide a standardized solution to this very problem.

The Quest for 'Decision-Grade Data'

In the high-stakes world of drug development, every decision to advance a compound costs millions of dollars. The industry's primary goal is to obtain "decision-grade data"—information so reliable and predictive that it can confidently guide these critical go/no-go choices. However, achieving this has been a persistent hurdle. The variability in creating and assessing 3D cell models, from cell sources and scaffold materials to culture conditions, can lead to inconsistent results that undermine confidence.

This challenge has fueled a push for New Approach Methodologies (NAMs), a class of technologies designed to replace or reduce reliance on animal testing with more human-relevant systems. The market is seeing a surge in advanced platforms like organ-on-a-chip systems and bioprinted tissues, but widespread adoption is often hindered by the steep learning curve and extensive in-house validation required.

“From a scientific perspective, Validated Solutions bring structure to what matters most: model design, biological confirmation, functional readouts, and expected performance in a specific use case,” said Sean Porazinski, PhD, Head of Scientific Programs at Inventia Life Science, in a statement. He explained that scientists receive a model blueprint that is already grounded in reproducible biology, backed by deep analysis to give them confidence in the human-relevant insights they generate.

A Blueprint for Reproducible Biology

Inventia's RASTRUM™ Validated Solutions are designed to function as a "lab-in-a-box" for specific diseases. Each solution is built upon the company's established RASTRUM platform, which uses high-precision, drop-on-demand bioprinting to construct 3D cell models at scale. The new offering standardizes this process by providing two key components: a Protocol Pack and a Data Pack.

The Protocol Pack provides a detailed, step-by-step recipe, defining all the inputs and parameters needed to print the 3D model consistently. This includes everything from the specific cell types and bio-inks to the precise printing commands for the RASTRUM instrument. The accompanying Data Pack serves as a certificate of authenticity, providing a wealth of information that validates the biological relevance of the model. It confirms that the printed tissue accurately captures the specific disease biology it is intended to model, giving researchers a solid, pre-verified baseline for their experiments.

“RASTRUM Validated Solutions are about helping drug discovery teams get to decision-grade data faster,” said Cameron Ferris, PhD, Co-Founder and COO of Inventia Life Science. “RASTRUM Allegro already gives teams the speed and reproducibility needed for scalable 3D workflows. With Validated Solutions, we are building on that foundation with predefined model blueprints... that will help teams adopt human-relevant 3D biology quickly and use it for stronger decisions.”

This approach aims to democratize access to sophisticated 3D biology, allowing labs without deep expertise in bioprinting or tissue engineering to integrate these powerful models into their standard workflows, thereby saving months of development and optimization time.

Targeting Intractable Diseases

The first two Validated Solutions released target diseases known for their complexity and the failure of traditional models: pancreatic ductal adenocarcinoma (PDAC) and fibroblast activation.

PDAC is one of the deadliest cancers, largely due to its dense, fibrous tumor microenvironment (TME) that acts as a physical barrier, preventing drugs from reaching the cancer cells. This stromal wall is notoriously difficult to replicate in standard lab models. The PDAC Validated Solution is designed to co-print tumor cells with stromal cells, creating a model that better mimics this critical tumor-stroma interaction. This allows researchers to more accurately test the efficacy of drugs designed to break down this barrier or target the supportive stromal cells themselves.

The Fibroblast Activation model addresses a biological process central to a range of diseases, from cancer to fibrosis. Fibroblasts are cells that produce the structural framework for tissues, but their over-activation can lead to the formation of scar tissue in organs like the lungs and liver, causing fibrotic diseases. They also play a key role in creating the supportive TME in many cancers. This model provides a controlled system to study the signals that trigger fibroblast activation and to test compounds that might inhibit this process, offering a valuable tool for both oncology and anti-fibrotic drug discovery.

Navigating a Competitive Landscape

Inventia is entering a dynamic and competitive space. Companies like CELLINK, Emulate, and InSphero have already made significant inroads by offering bioprinters, organ-on-a-chip platforms, and pre-made 3D spheroid models. However, Inventia is carving out a niche by combining a high-throughput bioprinting platform with fully validated, disease-specific model blueprints.

The key differentiator is the focus on providing a complete, ready-to-use solution that minimizes the user's burden of assay development and validation. While other companies may provide the tools or the final tissue product, Inventia's approach is to provide the validated process, empowering labs to produce their own consistent models on-demand. This strategy directly addresses feedback from drug discovery scientists who express a need for standardized, "off-the-shelf" solutions that can be easily integrated into existing high-throughput screening workflows without extensive setup.

By lowering the barrier to entry and ensuring reproducibility from the first experiment, the company hopes to accelerate the adoption of advanced 3D models across the industry. As pharmaceutical companies continue to seek more predictive and efficient research tools, the demand for such validated systems is expected to grow. Inventia has announced that additional RASTRUM Validated Solutions for other disease areas are already in development and scheduled for release later this year.